Sale

Psoriatic Arthritis Treatment Market

Global Psoriatic Arthritis Treatment Market Size, Share, Forecast: By Drug Class: Immunosuppressants, Biological Agents, Corticosteroids, Others; By Route of Administration: Oral, Parenteral, Topical; By Drug Type: Prescription, Over The Counter; By Distribution Channel: Hospital Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Psoriatic Arthritis Treatment Market Outlook

The psoriatic arthritis treatment market value was USD 12.19 billion in 2023, driven by the prevalence of psoriatic arthritis across the globe. The market size is anticipated to grow at a CAGR of 9.8% during the forecast period of 2024-2032 to achieve a value of USD 28.27 billion by 2032.

 

Psoriatic Arthritis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

It is estimated that psoriasis affects more than 125 million individuals around the globe, and psoriasis tends to create psoriatic arthritis in 30% of the population. The global industry for psoriatic arthritis treatment is influenced by an increasing acceptance of medical therapy by patients suffering from moderate to serious psoriatic arthritis.

 

Market Segmentation

Psoriatic arthritis is a chronic psoriasis-related degenerative disorder. Swollen fingers, toes, and tender joints, stiffness, lowered back pain, and pitted nails are prevalent symptoms of psoriatic arthritis. Psoriatic arthritis treatment market can be divided on the basis of segments like drug class, product type and administration route.

 

Psoriatic Arthritis Treatment Market By Segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF


On the basis of its drug class, the market can be widely categorised as:

  • NSAIDs 
  • DMARDs
  • Biologics 
  • Other

Based on its product type, the market can be bifurcated as prescription and OTC.

The different administration route available for psoriatic arthritis treatment are topical, oral and injectable.

The EMR report looks into the regional psoriatic arthritis treatment markets like the North America, Latin America, Europe, Middle East and Africa, and Asia Pacific.

 

Market Analysis

The intensive research taking place to provide treatment to the patients suffering from psoriasis condition is driving the global psoriatic arthritis treatment industry. The other factors aiding in the growth of the industry are investments by major companies in clinical R&D, new product launches, increasing disease prevalence and proactive government initiatives. The factors such as high cost of treatment, stringent regulatory approval and adverse effect of drugs may hinder the growth of the market in coming future.

 

Psoriatic Arthritis Treatment Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global psoriatic arthritis treatment industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

 

  • AbbVie Inc.
  • Janssen Global Services, LLC (Johnson & Johnson)
  • Novartis AG
  • Amgen Inc.
  • Biogen Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • UCB S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Others

 

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s five forces.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Route of Administration
  • Drug Type
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Immunosuppressants
  • Biological Agents
  • Corticosteroids
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Topical
Breakup by Drug Type
  • Prescription
  • Over The Counter
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AbbVie Inc.
  • Janssen Global Services, LLC (Johnson & Johnson)
  • Novartis AG
  • Amgen Inc.
  • Biogen Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • UCB S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Others

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Psoriatic Arthritis Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Psoriatic Arthritis Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Psoriatic Arthritis Epidemiology (2016-2031)
    5.3    Europe Psoriatic Arthritis Epidemiology (2016-2031)
    5.4    Asia-Pacific Psoriatic Arthritis Epidemiology (2016-2031)
    5.5    Latin America Psoriatic Arthritis Epidemiology (2016-2031)
    5.6    Middle East & Africa Psoriatic Arthritis Epidemiology (2016-2031)
6    Global Psoriatic Arthritis Treatment Market Overview 
    6.1    Global Psoriatic Arthritis Treatment Market Historical Value (2017-2023) 
    6.2    Global Psoriatic Arthritis Treatment Market Forecast Value (2024-2032)
7    Global Psoriatic Arthritis Treatment Market Landscape
    7.1    Psoriatic Arthritis Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Psoriatic Arthritis Therapeutics: Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Drug Type
        7.2.3    Analysis by Route of Administration
8    Psoriatic Arthritis Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Psoriatic Arthritis Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Psoriatic Arthritis Treatment Market Segmentation
    11.1    Global Psoriatic Arthritis Treatment Market by Drug Class
        11.1.1    Market Overview
        11.1.2    Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        11.1.3    Disease-Modifying Antirheumatic Drugs (DMARDs)
        11.1.4    Immunosuppressants
        11.1.5    Biological Agents
        11.1.6    Corticosteroids 
        11.1.7    Others
    11.2    Global Psoriatic Arthritis Treatment Market by Route of Administration
        11.2.1    Market Overview
        11.2.2    Oral
        11.2.3    Parenteral
        11.2.4    Topical
    11.3    Global Psoriatic Arthritis Treatment Market by Drug Type
        11.3.1    Market Overview
        11.3.2    Prescription
            11.3.2.1    Branded
            11.3.2.2    Generics
        11.3.3    Over The Counter
    11.4    Global Psoriatic Arthritis Treatment Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacies
        11.4.3    Retail Pharmacies
        11.4.4    Online Pharmacies
    11.5    Global Psoriatic Arthritis Treatment Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Psoriatic Arthritis Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Psoriatic Arthritis Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Psoriatic Arthritis Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Psoriatic Arthritis Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Psoriatic Arthritis Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    AbbVie Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Janssen Global Services, LLC (Johnson & Johnson)
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Novartis AG
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Amgen Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Biogen Inc.  
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Pfizer Inc.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Eli Lilly and Company
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    UCB S.A.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Bristol-Myers Squibb Company
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Merck & Co. Inc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Others
24    Psoriatic Arthritis Therapeutics - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket
    

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The value for psoriatic arthritis treatment market attained a value of USD 12.19 billion in 2023.

The market is expected to grow at a CAGR of 9.8% during the forecast period of 2024-2032, likely to attain a value of USD 28.27 billion by 2032.

The major drivers of the market include the increasing acceptance of medical therapy by patients suffering from moderate to serious psoriatic arthritis, new product launches, growing disease prevalence, and rising government initiatives.

The intensive research taking place to provide treatment to the patients suffering from psoriasis condition is the key industry trend propelling the growth of the market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading drug classes of psoriatic arthritis treatment in the industry are NSAIDs, DMARDs, and biologics, among others.

The significant product types in the market are prescription and OTC.

The major routes of administration of psoriatic arthritis treatment in the industry are topical, oral, and injectable.

The major players in the industry are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., UCB SA, and AstraZeneca plc, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER